The findings from this study and other recent case-control studies are reassuring regarding the use of RT in patients with early breast cancer. They indicate that the risk of leukemia secondary to such treatment is extremely small, if present at all. However, it is still possible that the use of RT may be associated with the risk of secondary solid tumors. Since the latency period to the development of these tumors is greater than that for leukemia, additional follow-up is required to be certain about the presence and magnitude of this risk.
ASJC Scopus subject areas
- Cancer Research